Epizyme - EPZM Stock Forecast, Price & News

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Epizyme Stock Performance

NASDAQ:EPZM traded down $0.01 during midday trading on Thursday, reaching $1.48. The stock had a trading volume of 138,430 shares, compared to its average volume of 2,386,301. Epizyme has a 12-month low of $0.41 and a 12-month high of $5.80. The firm has a fifty day simple moving average of $1.21 and a two-hundred day simple moving average of $1.13.

Epizyme (NASDAQ:EPZM - Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The firm had revenue of $8.70 million for the quarter, compared to analysts' expectations of $10.86 million. Epizyme had a negative net margin of 391.90% and a negative return on equity of 2,459.33%. During the same period last year, the firm posted ($0.69) EPS. On average, sell-side analysts expect that Epizyme will post -1.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Cowen lowered Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target for the company. in a research report on Monday, June 27th. Cowen downgraded Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target on the stock. in a research note on Monday, June 27th. StockNews.com cut Epizyme from a "hold" rating to a "sell" rating in a research note on Monday. HC Wainwright reduced their price target on shares of Epizyme from $8.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, June 3rd. Finally, Wedbush downgraded shares of Epizyme from an "outperform" rating to a "neutral" rating in a research report on Monday, June 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $3.00.